Fort Washington Investment Advisors 13F: Cuts HAE Stake by $40M

Fort Washington Investment Advisors reduced its position in Haemonetics Corporation (NYSE: HAE) by 379,989 shares, bringing its total holdings to 450,936 shares valued at about $47.5 million, according to its recent 13F filing on October 15, 2026. This represents a decrease of roughly 45.7% from its previous stake of 830,925 shares.

Other Institutional Activity in Haemonetics Corporation

Blackrock Inc. grew its holdings by 289,422 shares, ending with 5,909,258 shares worth around $698.9 million. Neuberger Berman Group, LLC increased its stake by 618,531 shares to 4,179,443 shares valued at approximately $494.3 million. However, Vanguard Portfolio Management LLC slightly reduced its position by 12,796 shares, leaving it with 2,546,394 shares worth about $301.2 million.

Haemonetics Corporation Stock Down 1.7%

Haemonetics is trading recently around $119.24, which is about 4.2% below the analyst target mean price of $124.50. The stock is currently above its 50-day moving average by 14.1% and significantly above its 200-day moving average by 55.7%. However, it is about 3.7% below its 52-week high of $123.77.

Recent Earnings

Haemonetics reported trailing twelve-month revenue of approximately $1.35 billion and an EPS of $2.06. The company's revenue growth year-over-year is 5.6%. The next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at Haemonetics Corporation

Mark W. Kroll, a director at Haemonetics, purchased 1,400 shares at an average price of $70.56 on November 10, 2025, totaling about $98,784. This transaction occurred prior to Fort Washington's recent reduction in its holdings.

Analysts Set New Price Targets

On September 3, 2026, Raymond James maintained an "Outperform" rating on the stock with a target of $125. Citigroup upgraded its rating to "Buy" on September 17, 2026, with a price target of $123, up from $92. BTIG also maintained a "Buy" rating with a target of $130 as of October 8, 2026.

About Haemonetics Corporation

Haemonetics Corporation is a medical technology company based in Boston, MA. It provides a suite of hospital technology solutions through its Plasma, Blood Center, and Hospital segments. The recent changes in institutional positions may reflect evolving strategies in the healthcare technology sector.

Bottom Line

Investors should note that Fort Washington’s filing reflects its holdings as of the reporting period and may not represent its current position. Keep an eye on Haemonetics' upcoming earnings report on November 5, 2026, for further insights into the company's performance.